

RECEIVED
CENTRAL FAX CENTER

APR 23 2008

In the claims:

Claim 1 (currently amended) A nutraceutical or pharmaceutical compositions rich in unsaturated fatty acids, wherein it contains ~~free or combined~~ α -linolenic acid or a salt or ester thereof, at a concentration ranging from 70 to 90% of the global weight, admixed with fatty acids having five and/or six double-bonds, in the form of capsules, granules, powder on a powdery carrier or of drinkable emulsions.

Cancel **Claim 2**.

Claim 3 (previously presented) A nutraceutical or pharmaceutical compositions of Claim 1, wherein α -linolenic acid is present as an adsorbate in a cellulose derivative or in a cyclodextrine.

Claim 4 (previously presented) A nutraceutical or pharmaceutical compositions of Claim 1, wherein the fatty acid with five double-bonds is eicosapentaenoic acid.

Claim 5 (previously presented) A nutraceutical or pharmaceutical composition of Claim 1, wherein the fatty acid with six double-bonds is docosahexaenoic acid.

Claim 6 (previously presented) A nutraceutical or pharmaceutical composition of Claim 4, wherein the fatty acid with five double-bonds is present as a fish oil selected from the group consisting of halibut oil, cod liver oil, haddock oil, tuna oil, sardine oil and shark oil.

Claim 7 (previously presented) A nutraceutical or pharmaceutical composition of Claim 5, wherein the six double-bond fatty acid is present as a fish oil selected from tuna oil and sardine oil.

Claim 8 (previously presented) A nutraceutical or pharmaceutical composition of Claim 1, wherein α -linolenic acid is present as an oil rich or concentrated in α -linolenic acid.

Claim 9 (previously presented) A nutraceutical or pharmaceutical composition of Claim 1, wherein α -linolenic acid is present as kiwi seed oil.

Claim 10 (currently amended) A nutraceutical or pharmaceutical composition of Claim 4, wherein eicosapentaenoic acid constitutes from 10 to 20% of the ~~global~~ total weight.

Claim 11 (currently amended) A nutraceutical or pharmaceutical composition of Claim 5, wherein docosahexaenoic acid constitutes from 25 to 35% of the ~~global~~ total weight.

Claim 12 (currently amended) A neutraceutical or pharmaceutical composition of Claim 1, which also contains ~~some~~ γ -linolenic acid.

Claim 13 (previously presented) A neutraceutical or pharmaceutical composition of Claim 1, containing from 800 to 1000 mg of α -linolenic acid, from 80 to 120 mg of eicosapentaenoic and from 250 to 300 mg of docosahexaenoic acid, in the form of capsules, granules, powder on a powdery carrier or drinkable emulsions.

Claim 14 (currently amended) A neutraceutical or pharmaceutical composition of Claim 1, wherein ~~the~~ an excipient or vehicle is as a neutral oil, stable towards rancidity, selected from the group consisting of almond oil, peanut oil, cotton seed oil, corn oil, water mixed with polysorbate and a mix water/ethanol mixed with polyethyleneglycol stearate is present.

Cancel Claims 15 and 16.

Add the following claim:

Claim 17 (new) A method of treating atheromatosis in warm-blooded animals comprising administering to warm-blooded in need thereof an effective amount of a composition rich in unsaturated fatty acids, wherein it contains α -linolenic acid or a salt or ester thereof, at a concentration ranging from 70 to 90% of the global weight,

admixed with fatty acids having five and/or six double-bonds, in the form of capsules, granules, powder on a powdery carrier or of drinkable emulsions of Claim 1.

Claim 18 (new) The method of Claim 17 wherein the fatty acid with 5 double bonds is eicosapentaenoic acid and it contains α -linolenic acid.

Claim 19 (new) The method of Claim 17 containing α -linolenic acid and the fatty acid of 6 double bonds is docosahexaenoic acid.